Skip to content
OpenCapital
Get started

Bio-Rad Laboratories, Inc. BIO.B Trading Securities in Marketable Securities

Trading Securities in Marketable Securities at other companies

Agilent Technologies logo
Agilent TechnologiesA
——
Bruker logo
BrukerBRKR
——
Illumina logo
IlluminaILMN
——

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×—
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.

The official record: Bio-Rad Laboratories, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bio-Rad Laboratories, Inc.'s trading securities in marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bio-Rad Laboratories, Inc.'s trading securities in marketable securities?
Bio-Rad Laboratories, Inc. (BIO.B) reported trading securities in marketable securities of $23.7M in Q1 2026.
How has Bio-Rad Laboratories, Inc.'s trading securities in marketable securities changed year-over-year?
Bio-Rad Laboratories, Inc.'s trading securities in marketable securities increased by 3.0% year-over-year, from $23M to $23.7M.
What is the long-term trend for Bio-Rad Laboratories, Inc.'s trading securities in marketable securities?
Over 2 years (2020 to 2025), Bio-Rad Laboratories, Inc.'s trading securities in marketable securities has grown at a 578.2% compound annual growth rate (CAGR), from $500K to $23M.